For Investors · Strategic Capital · Long-Horizon Partnership
A category-leading healthcare institution.
Built on mission.
AKC is India's largest single-specialty nephrology network — 250+ centres, 14 states, 18 years of clinical institution-building. The market is booming. The infrastructure to serve it is fragmented. The opportunity, for the right kind of capital partner, is to back the consolidator that is also the standard-setter.
The Investment Thesis
India's renal care category is among the country's largest, fastest-growing, and most fragmented healthcare segments. The institution capable of consolidating it at quality is the institution that will define the category. AKC has spent eighteen years building to be that institution — and is now selectively raising the capital to be the only one of its kind at national scale.AKC · Investor Overview · 2026
The Market Opportunity
A category large enough to matter.
Fragmented enough to consolidate.
India's chronic kidney disease burden is among the largest in the world. The care infrastructure to serve it is among the most underbuilt. The result is a market that is growing structurally at well above GDP, dominated by sub-scale operators, and primed for the institution that can combine quality with scale.
CKD Burden
220M
Indians at risk of chronic kidney disease — an estimated 17%+ of adults, driven by diabetes, hypertension, and an ageing population.
Dialysis Demand
15%+
Annual growth in dialysis demand — well ahead of healthcare-spend growth generally and of most other chronic-disease categories.
Underservice
~25%
Of population medically requiring dialysis are receiving it.
Why now
Diabetes and hypertension prevalence are rising rapidly across India, and CKD progression follows on a 10–15 year lag. The dialysis demand curve of the next two decades is already locked in by the disease prevalence of today.
Government tailwinds — PMJAY dialysis coverage, state-level schemes, National Dialysis Programme — are systematically expanding insured demand and formalising the market.
The market remains fragmented. Thousands of standalone units; two or three multi-state networks with genuine institutional capability.
Why AKC
Scale and standard, together. Most networks at AKC's scale do not have AKC's clinical institution-building; most institutions with AKC's clinical credibility do not have its scale.
The platform compounds. Every new centre adds to the data, every patient adds to the network, every nephrologist adds to the institution. The marginal-value-of-scale curve is steeper here than in most healthcare categories.
The mission is the moat. AKC has built what it has built because its founders cared enough to spend two decades on it.
The Six Pillars of the Moat
Why AKC is hard to replicate.
Healthcare moats are rarely about technology or capital alone. AKC's defensibility rests on six compounding pillars — each of which would take a competitor years to build, and which together would take decades.
I
Pillar OneThe Unreplicable Asset
Founder-Clinician Credibility
Eighteen years of standing in Indian nephrology, four founding clinicians from Mumbai's most respected hospitals, 85+ collective indexed publications. Capital cannot accelerate this; only time and quality can.
The single hardest thing to manufacture in Indian healthcare is the clinical credibility that earns the trust of nephrologists, hospitals, patients, and regulators simultaneously. AKC has it because its founders earned it personally, over careers spent at Bombay Hospital, Nanavati Max, and Hiranandani — and then spent eighteen years extending it into an institution.
Competitors with capital can build centres. They cannot manufacture the trust that decides which centre a senior consultant refers her patients to.
The credibility, evidenced
- Founder clinicians from Bombay Hospital, Max Nanavati, Dr. L H Hiranandani and Sushrut Hospital
- 85+ collective indexed publications, FRCP Edinburgh, ISN Education Ambassador roles
- 18 years of operational and clinical track record
- Inbound referral networks from Mumbai's senior medical community
II
Pillar TwoThe Professional Asset
Professional Leadership
A company built by professionals, for a clinical business. Nephrology expertise, operational discipline and management experience sit at the centre of every decision — from how centres are designed to how care is delivered.
Dialysis is not a business where financial scale alone creates advantage. Clinical judgement, experienced leadership and disciplined execution determine outcomes. Apex brings these capabilities together under one organisation, aligning clinical priorities with operational rigour.
The result is a company that understands both sides of the equation: the complexity of patient care and the realities of running a high-quality dialysis network. Decisions are made with professional accountability, not just commercial logic.
Professional depth, evidenced
- Clinician-informed leadership — clinical priorities embedded into operational and strategic decision-making
- Experienced management discipline — structured processes, accountability and performance management across the organisation
- Patient-first operating philosophy — decisions designed around quality, safety and continuity of care
- Institutional knowledge — professionals building systems and capabilities that compound with every centre, every team and every year
III
Pillar ThreeThe Compounding Asset
Operational Scale
Two hundred centres, ten states, eighteen years of running them. Procurement scale, technician training infrastructure, accreditation muscle — each of which gets stronger with every centre added.
Dialysis is, fundamentally, an operational business with clinical stakes. The economics turn on procurement, technician productivity, machine uptime, water purity, and centre utilisation — all of which scale-led operators do better than independents.
AKC's unit economics are not theoretical; they are stress-tested across two hundred centres and a decade of practice. A new centre activated in 2026 inherits everything the network has learned since 2007.
The scale, evidenced
- 250+ centres across 14 states — the largest single-specialty nephrology network in India
- Network-scale procurement on dialysers, tubing sets, EPO, iron, machines
- Centralised technician training and certification programme
- Mature SOPs for every aspect of unit operation, NABH-accreditation-ready
IV
Pillar FourThe Increasing-Returns Asset
Data & Technology
The Axis EHR, the Indian Renal Data System, the IIT Bombay operational research collaboration. These create increasing-returns moats — the platform becomes more valuable with every centre and every patient added.
AKC has spent years building what no other Indian renal organisation has: a nephrology-native technology and data layer. The Axis EHR captures every session, every adequacy measure, every intervention. The Indian Renal Data System (IRDS) aggregates this into India's first comprehensive renal registry.
The IIT Bombay collaboration brings operational research and AI/ML capability that is genuinely rare in Indian healthcare. The data asset compounds; the moat deepens; the optionality grows.
The platform, evidenced
- Axis — AKC's nephrology-native EHR, deployed across the network
- The Indian Renal Data System (IRDS) — the country's first comprehensive renal registry
- IIT Bombay collaboration on operational research and AI/ML in dialysis
- Optionality on technology licensing, research-data monetisation, and clinical-trial site infrastructure
V
Pillar FiveThe Trust Asset
Brand & Patient Trust
A chronic-disease patient on dialysis is making a decade-long decision. Brand is what decides which network they make it with — and AKC's brand has been built over eighteen years of consistent quality.
Dialysis patients do not switch easily. The relationship is long, the trust is irreplaceable, and the family decides for the patient as much as the patient does. Brand, in this category, is patient lifetime value compounded.
AKC's brand carries trust signals that newer entrants cannot manufacture: relationships with insurers and corporates, a recognised standard of quality, referral patterns from senior physicians, and the institutional credibility of founders who are still actively running the company.
The brand, evidenced
- Eighteen years of patient trust built across 250+ centres
- Established insurance, CGHS, ECHS empanelment, and corporate tie-ups
- NABH-aligned operations across the network
- High patient retention and inherited family-network referral
VI
Pillar SixThe Cultural Asset
Mission as Moat
The single most under-appreciated source of defensibility in healthcare is the kind of institution mission attracts and retains the kind of clinicians and operators others cannot.
AKC's mission — "to make a therapeutic impact in the universe of kidney disease" — is not marketing. It is the reason senior nephrologists who could earn more elsewhere choose AKC. It is the reason operators stay through the unglamorous decades. It is what makes the institution worth building, and worth building well.
Just capital cannot replicate this. A competitor with money can buy machines, lease centres, and hire technicians. They cannot manufacture the twenty-year culture that produces an institution. Mission, in this category, is structural advantage.
The mission, evidenced
- IRDS as public infrastructure — the data system is being built for the country, not just for AKC
- Talent retention at rates uncommon in Indian healthcare
Business Model & Growth
Recurring revenue. Endless geographies. Multiple models.
AKC's economics combine the predictability of chronic-disease recurring revenue with the optionality of multiple growth vectors — clinical, geographic, technological, and academic.
The Revenue Model
Recurring, diversified, resilient.
- Direct dialysis services — cash, insurance, PMJAY and state schemes
- Hospital partnerships — revenue-share, professional fees, technical services
- Clinical research services — investigator-initiated and industry-sponsored trials
- Technology & data — Axis platform optionality, IRDS research collaboration
The Growth Vectors
Geographic, clinical, technological.
- Geographic expansion — currently 10 of 28 states; significant white-space remains
- Service line expansion — home hemodialysis, peritoneal dialysis, transplant pre/post
- Asset-light partnership growth — hospital tie-ups, technical services, BOT models
- Technology platform extension — Axis as licensed infrastructure for other networks
- Research & clinical-trial monetisation — AKC as preferred Indian site network
- Selective international — opportunities in comparable markets
Mission & Impact
A return profile that includes the country.
For impact-aligned and ESG-mandated capital, AKC's measurable impact is not a side effect of the business — it is the business.
Lives
Patient Impact
Tens of thousands of patients receive AKC-standard dialysis annually — lives extended at quality.
Data
System Impact
IRDS is the data substrate for India's national kidney-care policy.
Talent
Workforce Impact
AKC and Apex School of Dialysis Technology are widening India's dialysis professionals pipeline faster than any university alone.
ESG 3
Goal Alignment
AKC's commitment to sustainable and inclusive healthcare is reflected in its advancement from Silver to Platinum status in the Aspire Impact assessment.
The People Building This
AKC is led by the four nephrologists who founded it, alongside an operational leadership team that has scaled the network across eighteen years and ten states. The people who built this institution are still the people running it.
Co-Founder
Dr. Shrirang Bichu
Nephrology · Bombay Hospital
Anchors AKC's COVID-era research and transplant outcomes work. 15+ publications.
Co-Founder
Dr. Jatin Kothari
Director, Nephrology — Nanavati Max · FRCP Edinburgh · ISN Education Ambassador
40+ publications. Leads AKC's clinical education and international partnerships. Shapes ApEx Pathshala.
Co-Founder
Dr. Rajesh Kumar
Nephrology · LH Hiranandani Hospital
Leads infection control and COVID research initiatives across the network. 10+ publications.
Founder & Director
Dr. Viswanath Billa
Associate Professor of Nephrology, Bombay Hospital
One of India's most cited nephrology faculty members. 20+ indexed publications. Anchors AKC's clinical leadership and research agenda.
Chief Executive Officer
Indranil Roy Choudhury
CEO · Apex Kidney Care
Drives AKC's expansion strategy, investor relations, and operational excellence across 250+ centres and fourteen states — translating the founders' clinical vision into a nationally scalable, technology-enabled kidney care network.
Operational Leadership
A Full Institutional Team
Operations · Clinical Governance · Technology · Finance
A complete institutional leadership bench across operations, clinical governance, technology, finance, and partnerships — stress-tested across two decades of network growth.
The Capital Already in Partnership
Two institutions have already taken the seat
at the AKC table.
AKC is honoured to count among its investors two institutions that exemplify what we look for in capital partnership — long horizons, healthcare conviction, mission alignment, and the operational seriousness that makes a board contribution meaningful. They are listed below.
Healthcare PE · India
Tata Capital
Healthcare Fund
The healthcare investment platform of one of India's most institutional names.
Tata Capital's dedicated healthcare fund backs growth-stage Indian healthcare businesses with the patient horizon, sectoral depth, and institutional gravitas that mature healthcare building demands. The Tata name carries weight in Indian healthcare for good reasons — nearly a century of building hospitals, research institutions, and public-spirited enterprises before the term ESG was invented.
Their partnership with AKC reflects a shared belief that category-leading Indian healthcare businesses are best built on Indian terms — with operational discipline, clinical depth, and a multi-decade view of what excellence looks like.
Why this partnership
Healthcare conviction, patient horizons, and institutional gravitas of the kind very few Indian funds can offer. The board contribution is operational, sectoral, and long-term.
Impact Capital · Global
Blue Earth
Capital
Institutional impact capital with a mandate for measurable health outcomes.
Blue Earth is an institutional impact investor backing healthcare and infrastructure businesses across emerging markets — with a mandate that demands both financial performance and measurable social outcomes. Their portfolio reflects a particular conviction in mission-led companies that scale.
Their partnership with AKC is a vote of confidence in the proposition this entire page has argued: that mission is not a feature of AKC's business — it is the structural advantage on which AKC's defensibility, talent retention, and long-term economics rest.
Why this partnership
Mission alignment, impact measurement discipline, and emerging-market healthcare experience — with the institutional rigour that makes board-level work substantive rather than ceremonial.
AKC engages with additional institutional capital on a selective and confidential basis. Full disclosure of investor terms, governance arrangements, and historical participation is shared during the diligence process, under appropriate confidentiality, with prospective partners whose profile aligns with the criteria below.
How We Choose Our Capital Partners
We are selective about our capital.
An institution like AKC is built across a generation, not a fund cycle. The capital that backs us must understand that. Below is what we look for in a partner — and what we offer, in turn.
i.
Long-horizon capital
AKC is a twenty-year institution-build, not a near-term exit. The patient capital that backs hospital chains, education institutions, and infrastructure is the right shape for what we are building.
ii.
Mission alignment
Capital that understands that "mission" in healthcare is not a feature; it is the moat. Capital that is willing to forgo a near-term margin point for a long-term standard improvement. Investors who would be proud to be on the page that tells AKC's story in ten years.
iii.
Healthcare conviction
Investors who have done healthcare work before, or who are willing to do the work to understand its operational and regulatory complexity. Generalist capital that treats healthcare as just another sector is not the right partner for this kind of build.
iv.
Operational value-add
A board contribution beyond capital — operational expertise, regulatory networks, international healthcare connections, talent introductions.
v.
Scale capacity
Capital that can grow with us. Follow-on capacity matters more than initial cheque size. An institutional balance sheet that can support AKC's geographic and clinical expansion across the next decade is the right partnership profile.
If this thesis is yours, we should talk.
AKC engages with capital partners on a selective and confidential basis. The materials below provide a starting view; the deeper conversation happens privately, with the founders and the CEO, after a mutual fit check.
The First Conversation